PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.

Trial Details

NCT ID
NCT06206096
Phase
PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically or cytologically confirmed non resectable, locally advanced or metastatic colorectal cancer;
  • No previous anti-tumor treatment for metastatic diseases;
  • KRAS/NRAS mutation;
  • Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →